C5G Stock Chart & Stats
€1.18
-€0.02(-1.20%)
At close: 4:00 PM EDT
€1.18
-€0.02(-1.20%)
Day’s Range― - ―
52-Week Range€0.54 - €3.83
Previous CloseN/A
Volume0.00
Average Volume (3M)60.00
Market Cap
€20.51M
Enterprise Value€576.03M
Total Cash (Recent Filing)€276.90M
Total Debt (Recent Filing)€9.90M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Oct 22, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume100
30 Day Avg. Volume60
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.86
Revenue Forecast (FY)€1.68M
Bulls Say, Bears Say
Bulls Say
Improved Balance-sheet LeverageLower leverage gives Orexo more financial flexibility than in prior periods when debt was higher and equity was thin. Although losses remain a concern, reduced debt-related pressure can help the company fund development, manage volatility, and withstand setbacks over the next several quarters.
Long-lived Intellectual PropertyLong IP runways can protect future products from direct generic competition and extend the period available to recover development investment. This supports the commercial durability of OX640 and GLP-1 initiatives, provided clinical progress, regulatory approval, and partnering are achieved.
Pipeline And Non-dilutive SupportPositive preclinical progress combined with substantial BARDA financing reduces Orexo's direct funding burden for OX390 and validates external interest in the program. Continued support can preserve internal resources for other pipeline assets while improving the route toward future commercialization or partnering.
Bears Say
Severe Profitability DeteriorationNegative gross profit and deeply negative operating and net margins indicate that current revenue does not cover Orexo's cost base. This weakens internally generated funding capacity, increases reliance on financing or partners, and makes sustained earnings recovery dependent on successful products and cost reductions.
Revenue Contraction And Weak RoyaltiesMaterial revenue contraction and very low quarterly sales reduce operating scale and make fixed development costs harder to absorb. Declining royalties from expiring agreements and generic competition further weaken the legacy revenue base, increasing dependence on pipeline launches and new commercial partnerships.
Cash Burn And Funding PressureThe substantial quarterly cash outflow can erode Orexo's available resources while the company remains loss-making. Planned OX640 spending adds a significant future funding requirement, and any delay in partnerships or financing could constrain development pace or require less attractive capital.
Orexo AB News
C5G FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was €0.54 and its highest was €3.83 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is €20.51M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 9 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -€0.199 earnings per share for the quarter, missing the consensus estimate of -€0.145 by -€0.054.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.19.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -€0.199 in its last earnings report, missing expectations of -€0.145. Following the earnings report the stock price went down -4.133%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in DE:C5G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
C5G Company Deck
C5G Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all DE:C5G earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―